Hidradenitis Suppurativa (Acne Inversa): More evidence on how to treat it

Epidemiology of Hidradenitis suppurativa (HS) also called Acne Inversa (Jemec) -Prevalence is anywhere between 0.0033% (genetic hypothesis) to 4% (self reporting in nurses) -In a big study in immigrants comparing with Spanish citizens, prevalence of HS was found to reach 0.2% up to 0.9% in Spanish citizens. prevalence is anywhere between 0.0033% (genetic hypothesis) to…

Details

The Benefits of Sunscreens: Protective Cellular Effects from Ultraviolet A Rays

Lipofucsin is the intracellular aggregate of oxidized proteins and lipids. It is a marker of autophagy and is stainable on immunochemistry with Sudan Black B (SBB) Ultraviolet A (UVA) damage induces DNA damage, oxidation of proteins and lipids, autophagy and subsequently apoptosis (provided exposure is long enough) In this study human cultures of fibroblasts were…

Details

Palmoplantar Psoriasis Treatment with Ustekinumab

Introduction: Palmoplantar psoriasis presents as sterile pustules with hyperkeratosis, erythema, scaling and fissuring on the palms and soles Treatment is challenging. topicals don’t really work and acitretin is not always effective. Methodology: prospective study 9 patients, mean age 48 years old ustekinumab administered subcutaneously at weeks 0,4 and then every 12 weeks evaluation with PPPASI…

Details

Adalimumab vs Etanercept in Quality of Life Improvement

Adalimumab showed a slightly higher reduction in PASI after 1 year, however it proved an equivalent efficacy to Etanercept after an extensive follow-up (up to 5 years) Contrarily to etanercept, adalimumab patients showed a progressive improvement with DLQI (84 to 77) For both groups, sustained response (PASI75 maintenance of results 60 months after initiation of…

Details

Biologic Therapy for Psoriasis: Paradoxical Reactivation of Psoriasis on Infliximab

Infliximab is an anti-TNF biologic It is used in the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease A case report from Spain: 32 year old female known for Crohn’s disease no response to mesalazine and systemic corticosteroids was subsequently put on infliximab at a dosage 5mg/kg for a duration of 10 years she…

Details